RBPJ and neoplasm: Moreover, combinatorial treatment of E.G7-OVA tumour-bearing mice with Rbpj-deficient OT-I cells with anti-PD-L1 enhanced antitumour effects compared with control groups (Fig. 5h), which suggested that targeting Rbpj in CTLs also boosts ICB response in the lymphoma model.